Form 4: Fulgent Genetics CFO Paul Kim Reports Stock Transactions Following RSU Vesting
SEC Form 4 Filing
CFO and Treasurer of Fulgent Genetics, Paul Kim, reports the acquisition and disposal of company stock related to the vesting of performance-based and regular restricted stock units (RSUs), with shares withheld to cover tax obligations.
Summary
- Paul Kim, CFO and Treasurer of Fulgent Genetics, filed a Form 4 detailing changes in beneficial ownership of company stock.
- The reported transactions occurred on February 25 and 26, 2025.
- These transactions involve the vesting of performance-based restricted stock units (RSUs) granted on February 28, 2022, February 23, 2023, and February 26, 2024.
- Kim also acquired restricted stock units that vest over three years, starting March 1, 2026.
- Shares were withheld to satisfy tax obligations arising from the vesting of these RSUs, with a price of $16.29 on February 25, 2025 and $16.24 on February 26, 2025.
- Following these transactions, Kim directly owns 249,838 shares of Fulgent Genetics common stock.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing detailing stock transactions related to executive compensation. It doesn't contain any particularly positive or negative information, hence a neutral sentiment score.
Positives
- The vesting of performance-based RSUs suggests that certain performance milestones were achieved.
- The reported transactions reflect ongoing compensation and alignment of the CFO's interests with the company's performance.
Future Outlook
The restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2025, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date.
Industry Context
Form 4 filings are routine disclosures for company insiders and provide transparency into their transactions in company stock. The vesting of RSUs is a common form of executive compensation in the biotechnology and genetics industry.
Comparison to Industry Standards
- Stock-based compensation is a common practice across the biotech industry, used to attract and retain talent.
- Companies like Illumina, Thermo Fisher Scientific, and Danaher also utilize RSUs and stock options as part of their executive compensation packages.
- The vesting schedules and performance metrics associated with RSUs vary depending on the company's specific goals and compensation philosophy.
Stakeholder Impact
- The transactions have a minor impact on shareholders, as they reflect the ongoing compensation of a key executive.
- Employees may view the vesting of RSUs as a positive sign of the company's commitment to its employees.
Key Dates
| Date | Description |
|---|---|
| 2022/02/28 | Date of grant for performance-based restricted stock units. |
| 2023/02/23 | Date of grant for performance-based restricted stock units. |
| 2024/02/26 | Date of grant for performance-based and regular restricted stock units. |
| 2025/02/25 | Date of stock transactions related to vesting of performance-based RSUs. |
| 2025/02/26 | Date of stock transactions related to vesting of performance-based RSUs. |
| 2025/02/27 | Date of signature on the Form 4 filing. |
| 2026/03/01 | Start date for vesting of restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.